Lymphoid Malignancies in Ataxia-Telangiectasia: Experience with Novel Targeted Therapies

Patients with ataxia-telangiectasia (AT) face unique challenges in managing lymphoid malignancies due to heightened sensitivity to chemotherapy and radiation, requiring alternative treatment strategies. This report presents three cases demonstrating the successful integration of targeted therapies: ibrutinib for diffuse large B-cell lymphoma, alemtuzumab for T-cell prolymphocytic leukemia, and venetoclax for early T-cell precursor acute lymphoblastic leukemia. These cases highlight the potential of targeted agents to improve outcomes while minimizing toxicity. Our findings underscore the need for further research to optimize treatment approaches in this high-risk population, offering novel insights into personalized therapy for patients with AT.